Skip Navigation LinksHome > December 2013 - Volume 19 - Issue 13 > Cost-effectiveness of Nonmelanoma Skin Cancer Screening in C...
Inflammatory Bowel Diseases:
doi: 10.1097/01.MIB.0000435850.17263.13
Original Clinical Articles

Cost-effectiveness of Nonmelanoma Skin Cancer Screening in Crohn's Disease Patients

Okafor, Philip N. MD MPH*; Stallwood, Christopher G. MD*; Nguyen, Linda MD; Sahni, Debjani MD; Wasan, Sharmeel K. MD*; Farraye, Francis A. MD, MSc*; Erim, Daniel O. MD, MS

Collapse Box

Abstract

Background:

Several studies have demonstrated an increased risk of nonmelanoma skin cancer (NMSC) in patients with inflammatory bowel disease, with the greatest risk in patients with Crohn's disease (CD). We investigated the cost-effectiveness of NMSC screening in patients with CD.

Methods:

A mathematical model was used to compare lifetime costs, life expectancies, and benefits of NMSC screening in a hypothetical cohort of 100,000 patients with CD. Strategies studied include: (1) Treat NMSC cases as they present and follow affected patients annually; (2) Screen patients with CD annually once they turn 50 years old, treat NMSC cases as they present and follow affected patients annually; (3) Screen patients with CD annually once they start receiving thiopurines, treat NMSC cases as they present and follow affected patients annually; (4) Screen patients with CD annually when they turn 50 years old or start receiving thiopurines, treat NMSC cases as they present, and follow affected patients annually; (5) Screen all patients with CD annually. These strategies were then studied on a biennial basis, accounting for 10 competing strategies.

Results:

Screening all patients with CD annually proved the most cost-effective strategy with an average lifetime cost of more than $333,000, a quality-adjusted life expectancy of about 26 QALYs (95% confidence interval: 22–29), ICER of $3263/QALY, and led to early detection of about 94% of incident NMSC cases. The next best strategy was screening all CD patients biennially with an average lifetime cost of more than $328,000 with 24.5 QALYs (95% confidence interval: 21–25). Only 47% of new NMSC cases were detected early with this strategy.

Conclusion:

At a willingness-to-pay threshold of $50,000, screening all patients with CD annually for NMSC proved the most cost-effective strategy.

Copyright © 2013 Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.